BridgeBio Pharma, Inc. remains a Buy, driven by Attruby’s strong U.S. launch and favorable competitive dynamics. Learn more ...
BridgeBio Pharma recently reported a strong and accelerating launch of its heart drug Attruby, with rapid growth in unique patient prescriptions and prescribers, supported by compelling clinical ...
Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...
CM, often mistaken for other heart conditions, where earlier diagnosis and treatment may help improve outcomes 1 PALO ALTO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: ...
As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...
BridgeBio Pharma has secured a $300 million upfront payment through a royalty financing agreement with HealthCare Royalty and Blue Owl Capital, which will bolster its financial position and support ...
BridgeBio's Attruby launch crushed expectations, with Q1 revenue triple analyst estimates, driven by higher-than-expected conversion rates and minimal free trial usage. Competitive threats from ...
(RTTNews) - BridgeBio Pharma, Inc. (BBIO), a commercial-stage company, reported narrower net loss for the fourth-quarter, while revenue surged from the prior year on improved product revenue. For the ...
BridgeBio (BBIO) rose 6.6% after a court filing disclosed a settlement in a generic patent case over Pfizer's (PFE) Vyndamax ...
Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. BridgeBio’s recently ...
Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results